Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CODEBREAK Sotorasib in Previously Treated KRAS p.G12C NSCLC
2024-510837-16-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sotorasib in non-small cell lung cancer (NSCLC), sponsored by Gustave Roussy. Primary endpoints: Objective response (OR) by RECIST v1.1, Progression-free survival (PFS) and 1 more. Planned start Apr 2024; status: authorised.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-510837-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510837-16-00.